<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn></journal-meta><article-meta><article-id pub-id-type="pmid">7981069</article-id><article-id pub-id-type="pmc">2033694</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Comparison of granisetron alone and granisetron plus dexamethasone in the prophylaxis of cytotoxic-induced emesis.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Carmichael</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bessell</surname><given-names>E. M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Harris</surname><given-names>A. L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hutcheon</surname><given-names>A. W.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Dawes</surname><given-names>P. J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Daniels</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bessel</surname><given-names>E. M.</given-names></name></contrib></contrib-group><aff>CRC Academic Unit of Clinical Oncology, Nottingham City Hospital Trust, UK.</aff><pub-date pub-type="ppub"><month>12</month><year>1994</year></pub-date><volume>70</volume><issue>6</issue><fpage>1161</fpage><lpage>1164</lpage><abstract><p>Two hundred and seventy-eight adult chemonaive patients, receiving moderately emetogenic chemotherapy were randomly allocated to receive either intravenous (i.v.) granisetron 3 mg plus i.v. dexamethasone 8 mg or i.v. granisetron 3 mg plus i.v. placebo dexamethasone prior to chemotherapy. Eight-two per cent of all patients recruited were female, and 91% of all patients consumed less than 10 units of alcohol per week, suggesting a study population with an increased risk of nausea and vomiting. In the first 24 h 85% of patients who received granisetron plus dexamethasone were complete responders compared with 75.9% of the patients receiving granisetron alone (P = 0.053). There were statistically significant improvements in complete response over 7 days (P = 0.029) and in the numbers of patients receiving rescue antiemetic (P = 0.0004). Toxicity was minimal with no significant differences between treatment groups. These results confirm the antiemetic activity of granisetron and show that it has an additive effect in combination with dexamethasone.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00058-0129.tif" xlink:title="scanned-page" xlink:role="1161" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00058-0130.tif" xlink:title="scanned-page" xlink:role="1162" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00058-0131.tif" xlink:title="scanned-page" xlink:role="1163" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00058-0132.tif" xlink:title="scanned-page" xlink:role="1164" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

